WJ-39
WJ-39 is an orally active aldose reductase (AR) inhibitor. WJ-39 improves tubular damage in diabetic nephropathy rats by activating PINK1/Parkin signaling, promoting mitophagy, and attenuating apoptosis[1].
Product Specifications
CAS Number
3009908-95-3
UNSPSC
12352005
Target
Aldose Reductase; Apoptosis; Mitochondrial Metabolism; Mitophagy
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/wj-39.html
Concentration
10mM
Purity
99.60
Solubility
DMSO : ≥ 350 mg/mL
Smiles
COC1=CC=C(N(CC(O[K])=O)C=C(CC2=CC=CC(Cl)=C2Cl)C3=O)C3=C1
Molecular Formula
C19H14Cl2KNO4
Molecular Weight
430.32
References & Citations
[1]Yang L, et al. An aldose reductase inhibitor, WJ-39, ameliorates renal tubular injury in diabetic nephropathy by activating PINK1/Parkin signaling. Eur J Pharmacol. 2024 Mar 15;967:176376.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
